Premium
Determinants of overall quality of life in preterminal cancer patients
Author(s) -
Beijer Sandra,
Kempen Gertrudis I.J.M.,
PijlsJohannesma Madelon C.G.,
de Graeff Alexander,
Dagnelie Pieter C.
Publication year - 2008
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.23497
Subject(s) - quality of life (healthcare) , medicine , cancer , multivariate analysis , lung cancer , nausea , disease , clinical psychology , nursing
Recently, a few studies reported that fatigue was a predominant contributor to patient‐perceived overall QoL in patients with different types of cancer in a relatively early stage of disease. In the present study, we aimed to investigate whether fatigue is also a major contributor to overall QoL in preterminal cancer patients. Ninety‐eight preterminal cancer patients, mainly lung (44%) and gastrointestinal cancer (25%), with an estimated life expectancy of 1–6 months were included. QoL domains as well as overall QoL were measured using the EORTC QLQ‐C30 questionnaire. Data were analysed by Pearson's correlations and multivariate modelling. Fatigue showed the strongest correlation with overall QoL ( r = −0.63, p < 0.001), followed in decreasing order by role functioning ( r = 0.53), physical functioning ( r = 0.47), social functioning ( r = 0.44), nausea ( r = −0.37), cognitive functioning ( r = 0.33), appetite loss ( r = −0.31), dyspnea ( r = −0.26) and emotional functioning ( r = 0.24). Multivariate analysis confirmed that the fatigue scale paid by far the highest individual contribution to overall QoL (standardized regression coefficient (SRC): −0.41, p = 0.002), followed by social functioning (SRC: 0.18, p = 0.05). None of the other domains or symptom scales contributed independently to overall QoL. Our results clearly demonstrate that, in preterminal cancer patients, fatigue is a major contributor of overall QoL, corroborating reports in cancer patients in earlier disease stages. © 2008 Wiley‐Liss, Inc.